Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Headlines,Tandem Diabetes Care shares saw a significant rise after a crucial EU approval for its insulin delivery system.,The ...

Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Despite insufficient data, writing panel will give recommendations for preparation, transfer, and follow-up for youth with ...

For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...

Investing.com - Tandem Diabetes Care (NASDAQ: TNDM) reported third quarter EPS of $-0.51, $0.03 worse than the analyst estimate of $-0.48. Revenue for the quarter came in at... Tandem Diabetes ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Continuous Glucose Monitoring Market is Growing at a CAGR of 7.80%, Driven by the Increasing Prevalence of Prediabetes ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Lake Street analyst Brooks O’Neil maintained a Buy rating on Accuray (ARAY – Research Report) today and set a price target of ...